Abstract
Background: Chronic rhinosinusitis with nasal polyps is a predominantly type-2 mediated inflammatory disease with high symptom and quality of life burden. Dupilumab significantly improved 22-item Sino-Nasal Outcome Test (SNOT-22) total score vs placebo (PBO) in SINUS-24 and SINUS-52 trials (NCT02912468; NCT02898454).
Objectives: Post hoc analysis of pooled SINUS-24 and SINUS-52 to identify the SNOT-22 items most important to patients (pts), assess the effect of dupilumab on these items, and association with objective disease measures.
Methods: Nasal polyp (NPS) and Lund-Mackay (LMK) scores were assessed in pts with and without improvement at Wk 24 in the SNOT-22 items ranked most important by pts at baseline (BL).
Results: Decreased sense of smell/taste and nasal blockage were the most important SNOT-22 items at BL (cited important by 87% and 82% of pts, respectively). More dupilumab (N=438) vs PBO (N=286) pts improved in these items at Wk 24 (smell/taste: 76.7% vs 30.4%; nasal blockage: 79.5% vs 44.4%). Dupilumab significantly improved NPS and LMK in all pts regardless of improvement in SNOT-22 items, with the greatest treatment effect seen in pts who had an improvement (Table below).
Conclusions: A higher percentage of dupilumab-treated pts improved in symptoms most important to pts (smell/taste; nasal blockage) vs PBO. Improvement in these symptoms signals greater improvement in objective measures (LMK and NPS).
| SNOT-22 item improvement (Wk 24) | ||
| Least squares mean difference vs PBO (Wk 24) | Smell/taste Yes/no | Nasal blockage Yes/no |
| NPS | –1.78*/–1.19* | –1.90*/–1.01* |
| LMK | –5.77*/–4.26* | –6.22*/–3.28* |
| *P<0.0001 vs PBO | ||
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2520.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
